川穹内酯联合阿托伐他汀对 VCAM-1和 PAI-1的抑制作用和抗动脉粥样硬化作用研究

摘要

目的：分析川穹内酯联合阿托伐他汀对VCAM-1和PAI-1的抑制作用，并研究两类药物联用对抗动脉粥样硬化的意义。方法：以2010年5月-2013年5月间于我院接受治疗的198例动脉粥样硬化为研究对象，以随机数字表法将其划分为观察组和对照组；对照组患者在常规保守治疗的基础上联用阿托伐他汀；观察组在对照组的基础上联用川穹内酯。对比治疗前后VCAM-1和PAI-1的血清浓度变化，统计血液生化检测及超声动脉检测结果。结果：①治疗后，两组患者两指标均上升，检测发现观察组VCAM-1和PAI-1明显低于对照组，组间差异具备统计学意义（P＜0．05）。②TC、LDL-C、HDL-C及颈动脉IMT和斑块Crous积分的变化均显示，观察组各指标改善情况明显优于对照组，对比差异均显著（P＜0．05）。结论：以川穹内酯联合阿托伐他汀；可有效抑制VCAM-1和PAI-1的表达；提升动脉粥样硬化治疗效果。%Objectives:To analysis the effect of resistance to VCAM-1 and PAI-1 from LigusticumchuanxiongHort com-bined with atorvastatin,as well as the effect of anti-atherosclerotic from them.Methods:We chose 198 cases of athero-sclerosis accepted by our hospital during May 2010 to May 2013 as the research object.Patients selected treatment scheme on their own accords,and by which we divided them into observation group and control group.Patients in control group used conventional conservative treatment to treat disease,while patients in Observation Group applied Ligusticum-chuanxiongHort on the basis of the observation group.We compared the change of serum concentration of VCAM-1 and PAI-1 ,and made an account of blood biochemical testing and ultrasonic testing results.Then,we evaluated the efficacy of the treatment of atherosclerosis.Results:(1 )After treatment,patients in both groups increased by two indicators,the observation group detected VCAM-1 and PAI-1 was significantly lower than the control group,with statistically significant differences between groups (P<0.05).(2)The change of main indicators of atherosclerosis data:TC,LDL-C,HDL-C and carotid’s IMT as well as plaque’s Crous score,in observation group were much better than the change in Control Group,contrast differences were significantly (P<0.05).Conclusion:Combining LigusticumchuanxiongHort with ator-vastatin as treatment scheme can decline the amount of VCAM-1 and PAI-1 much better than using atorvastatin alone. And the combination can also improve the curative effect towards atherosclerotic,which has promotion value.